Jae-Gyun Jeong

Jae-Gyun Jeong is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 4 patents, his work focuses on enhancing the stability and efficacy of antibodies used in cancer treatment.

Latest Patents

One of his latest patents is titled "Anti-c-Met antibody showing enhanced stability or antigen-binding fragments thereof." This invention relates to an anti-c-Met antibody that demonstrates improved stability and reduced immunogenicity compared to its parent antibody, 1E4. The enhanced properties of this antibody lead to reduced production costs, improved efficacy, and minimized side effects. Another notable patent is "Anti-Sialyl Tn chimeric antigen receptors," which provides improved compositions for adoptive cell therapies targeting cancers that express the glycoepitope STn on TAG-72.

Career Highlights

Throughout his career, Jae-Gyun Jeong has worked with notable companies such as Helixmith Co., Ltd and Cartexell Inc. His innovative approaches have positioned him as a key player in the biotechnology sector, contributing to advancements in cancer therapies.

Collaborations

Jae-Gyun Jeong has collaborated with several professionals in his field, including Seung Shin Yu and Dongsik Kim. These collaborations have further enriched his research and development efforts.

Conclusion

Jae-Gyun Jeong's contributions to antibody development highlight his innovative spirit and dedication to improving cancer therapies. His patents reflect a commitment to advancing medical science and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.